logo-loader
viewC4X Discovery Holdings PLC

C4X Discovery in advanced discussions to partner its 'world-leading' NRF-2 programme

Clive Dix, chief executive of C4X Discovery Holdings plc (LON:C4XD), recaps on recent significant developments following the release of their interims for the six months to the end of January 2019.

Dix says confidential discussions with multiple potential partners are being held for its NRF-2 activator programme which is focused on chronic obstructive pulmonary disease and pulmonary arterial hypertension as well as sickle cell disease.

Quick facts: C4X Discovery Holdings PLC

Price: 12 GBX

AIM:C4XD
Market: AIM
Market Cap: £13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: C4X Discovery fully cashed up and sees big potential for its...

C4X Discovery Holdings plc's (LON:C4XD) Clive Dix speaks to Proactive London's Andrew Scott following the news they've raised around £6.6mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates. While expressing regret for the level at which...

on 25/10/19

2 min read